Most Down Articles

Published in last 1 year|In last 2 years|In last 3 years|All|Most Downloaded in Recent Month|Most Downloaded in Recent Year|

In last 2 years

Please wait a minute...


For Selected: Download Citations EndNote Ris BibTeX Toggle Thumbnails

Select

Journal of International Oncology 2022, 49 (11): 641-657. DOI:10.3760/cma.j.cn371439-20221011-00129 Abstract（ 732） HTML（ 261） PDF（pc）（2785KB）（ 841） Knowledge map Save Table and Figures|Reference|Related Articles|Metrics|Comments（0）

Select

Journal of International Oncology 2023, 50 (3): 129-137. DOI:10.3760/cma.j.cn371439-20230217-00027 Abstract（ 307） HTML（ 43） PDF（pc）（4432KB）（ 789） Knowledge map Save Table and Figures|Reference|Related Articles|Metrics|Comments（0）

Select

Predictive value of biomarkers in immunotherapy of advanced non-small cell lung cancer Lei Yan, Zhang Gehong Journal of International Oncology 2022, 49 (12): 739-744. DOI:10.3760/cma.j.cn371439-20220816-00145 Abstract（ 290） HTML（ 28） PDF（pc）（819KB）（ 183） Knowledge map Save Immunotherapy, especially immune checkpoint inhibitor, has revolutionized the treatment mode of advanced non-small cell lung cancer. The predictive effect of programmed death-ligand 1 and tumor mutation burden for treatment response has been fully proved. Neither of which can avoid some problems, including tumor heterogeneity, inconsistent detection methods and identification standards. The studies have found that some novel biomarkers are related to the efficacy of immunotherapy, such as mismatch repair deficiency and microsatellite instability, driver gene mutation, routine peripheral blood biomarkers, circulating tumor cells, circulating tumor DNA and so on. Further research on the predictive value of biomarkers in tumor tissue and peripheral blood in immunotherapy of advanced non-small cell lung cancer can provide a reference for instituting clinical treatment plan. Reference|Related Articles|Metrics|Comments（0）

Select

Immunotherapy for EGFR-mutant non-small cell lung cancer after EGFR-TKI acquired resistance Zhang Bixia, Ding Jianghua Journal of International Oncology 2023, 50 (2): 97-101. DOI:10.3760/cma.j.cn371439-20220719-00020 Abstract（ 138） HTML（ 8） PDF（pc）（752KB）（ 161） Knowledge map Save Epidermal growth factor receptor （EGFR）-mutant advanced non-small cell lung cancer （NSCLC） was previously regarded as a cold tumor according to tumor immune microenvironment （TIME）. However，recent studies have found that EGFR-tyrosine kinase inhibitors （EGFR-TKIs） treatment can transform the host immunity from immunosuppressive to immunosupportive state，bringing new hope for immunotherapy. There are four main therapeutic strategies for patients after EGFR-TKIs acquired resistance： immunotherapy alone （Im），immunotherapy plus chemotherapy （Im+C），immunotherapy plus antiangiogenic drugs （Im+A），and immunotherapy combined with antiangiogenic drugs and chemotherapy （Im+A+C）. Among them，the efficacy of Im is extremely limited，being significantly lower than that of chemotherapy alone，while there is still scarce evidence for the efficacy of Im+A with few clinical studies. The combination of Im+C and Im+A+C shows better efficacy than chemotherapy alone. Im+A+C has a superior clinical outcome to Im+C. Additionally，the EGFR L858R mutation subgroup benefits more from Im+C than the EGFR 19 del mutation subgroup. The T790M-negative subgroup has a greater benefit from Im+A+C than the T790M-positive subgroup. In general，the strategy of combining immunotherapy with chemotherapy and/or an antiangiogenic drug represents a novel and promising method for treating EGFR-mutant NSCLC after EGFR-TKI failure. Reference|Related Articles|Metrics|Comments（0）

Select

Analysis on the incidence and risk factors of pneumonia in patients with lung cancer receiving thoracic radiotherapy and immunotherapy Huang Huayu, Song Qibin, Gong Hongyun, Song Jia Journal of International Oncology 2022, 49 (12): 718-723. DOI:10.3760/cma.j.cn371439-20220726-00141 Abstract（ 227） HTML（ 16） PDF（pc）（776KB）（ 157） Knowledge map Save ObjectiveTo analyze the incidence, risk factors and occurrence time of radiation pneumonia （RP） and immune checkpoint inhibitor-related pneumonia （CIP） in patients with lung cancer and lung metastatic cancer who received both thoracic radiotherapy and immunotherapy.MethodsThe clinicopathological data of 137 patients with lung cancer and lung metastatic cancer receiving thoracic radiotherapy and at least one cycle of immunotherapy from January 2019 to January 2022 in Renmin Hospital of Wuhan University were retrospectively analyzed. The occurrence of RP and CIP was determined according to the clinical symptoms and thin-slice chest CT. The risk factors of symptomatic RP were evaluated by univariate and multivariate analyses of clinical data and treatment plan. The relationship between the occurrence time of symptomatic RP and the sequence of thoracic radiotherapy and immunotherapy was compared.ResultsIn the 137 patients with lung cancer and lung metastatic cancer who received both thoracic radiotherapy and immunotherapy, symptomatic RP was observed in 42 patients （30.7%）, including grade 2 RP in 33 patients （24.1%）, grade 3 RP in 6 patients （4.4%）, grade 4 RP in 1 patient （0.7%）, and grade 5 RP in 2 patients （1.5%）. The incidence of symptomatic RP was 40.0% （28/70） in patients who received thoracic radiation concurrent with immunotherapy and 20.9% （14/67） in non-synchronous patients, and the incidence of severe RP was 10.0% （7/70） and 3.0% （2/67） respectively. CIP was observed in 11 （8.0%） of 137 patients, including grade 2 CIP in 4 patients （2.9%）, grade 3 CIP in 6 patients （4.4%）, grade 5 CIP in 1 patient （0.7%）. There were 54.5% （6/11） of CIP patients with prior or concurrent symptomatic RP. Univariate analysis showed that smoking history （χ2=9.85,P=0.002）, chronic obstructive pulmonary disease （COPD） history （χ2=31.34,P<0.001）, thoracic radiotherapy concurrent with immunotherapy （χ2=5.88,P=0.015）, total radiotherapy dose （χ2=8.57,P=0.003） were associated with symptomatic RP. Multivariate logistic regression analysis showed that COPD history （OR=9.96, 95%CI: 3.40-29.14,P<0.001）, thoracic radiotherapy concurrent with immunotherapy （OR=2.84, 95%CI: 1.15-7.00,P=0.024）, and total radiotherapy dose ≥60 Gy （OR=4.76, 95%CI: 1.68-13.50,P=0.003） were independent risk factors for symptomatic RP. RP occurred earlier in patients who received immunotherapy before thoracic radiotherapy [68.5 d （47.0 d, 101.8 d）] than in patients who received immunotherapy after thoracic radiotherapy [117.5 d （79.0 d, 166.3 d）], with a statistically significant difference （Z=2.54,P=0.010）.ConclusionThe incidence of symptomatic RP is high in patients who receive both thoracic radiotherapy and immunotherapy. The history of COPD, thoracic radiotherapy concurrent with immunotherapy, and the total radiotherapy dose ≥60 Gy are independent influencing factors of symptomatic RP in patients with thoracic radiotherapy combined with immunotherapy. Symptomatic RP occurs earlier in patients who receive immunotherapy before thoracic radiotherapy than in patients who receive immunotherapy after thoracic radiotherapy. Table and Figures|Reference|Related Articles|Metrics|Comments（0）

Select

Journal of International Oncology 2022, 49 (12): 711-717. DOI:10.3760/cma.j.cn371439-20220911-00140 Abstract（ 174） HTML（ 16） PDF（pc）（766KB）（ 156） Knowledge map Save Reference|Related Articles|Metrics|Comments（0）

Select

Research progress of ferroptosis in the treatment of leukemia Zhou Xinyu, Jia Xiuhong Journal of International Oncology 2022, 49 (12): 759-762. DOI:10.3760/cma.j.cn371439-20220816-00149 Abstract（ 171） HTML（ 10） PDF（pc）（757KB）（ 154） Knowledge map Save Leukemia is a group of hematologic malignancie. Ferroptosis is a novel of cell death caused by iron-dependent lipid peroxidation accumulation, which participates in the occurrence and development of leukemia. Activation of different regulatory sites in the ferroptosis pathway can promote the death of leukemia cells. Therefore, it can provide a new direction for the treatment of leukemia by inducing ferroptosis of cells. Reference|Related Articles|Metrics|Comments（0）

Select

Journal of International Oncology 2022, 49 (12): 705-710. DOI:10.3760/cma.j.cn371439-20220725-00139 Abstract（ 195） HTML（ 22） PDF（pc）（1571KB）（ 144） Knowledge map Save Table and Figures|Reference|Related Articles|Metrics|Comments（0）

Select

Effects of radiation-associated miRNA in radiotherapy for breast cancer Jin Jiahui, Chen Cunhai, Ma Xuezhen Journal of International Oncology 2022, 49 (12): 735-738. DOI:10.3760/cma.j.cn371439-20220805-00144 Abstract（ 199） HTML（ 16） PDF（pc）（786KB）（ 143） Knowledge map Save Breast cancer is the most common cancer in women, and radiotherapy is an important method of its treatment. The outcome of radiotherapy greatly depends on radiosensitivity of cancer cells. The key pathways of microRNAs （miRNAs） involved in breast cancer radiotherapy response include DNA damage repair, apoptosis, cell cycle arrest, autophagy and related signaling pathways. This article reviews the role of miRNAs in regulating the response of breast cancer to radiotherapy and related signaling pathways. To explore the role of miRNAs in regulating the treatment response of breast cancer to radiotherapy and related signaling pathways, it can provide reference for miRNAs to be used as an indicator to evaluate the diagnosis, prognosis and radiotherapy efficacy of breast cancer. Reference|Related Articles|Metrics|Comments（0）

Select

Clinical efficacy of osimertinib and icotinib in first-line treatment of EGFR-positive metastatic NSCLC Ning Tingting, Hu Qinyong, Li Qian, Yang Pengcheng Journal of International Oncology 2023, 50 (2): 65-70. DOI:10.3760/cma.j.cn371439-20221028-00014 Abstract（ 199） HTML（ 14） PDF（pc）（885KB）（ 141） Knowledge map Save ObjectiveTo investigate the real-world efficacy of osimertinib and icotinib in metastatic non-small cell lung carcinoma （NSCLC） patients.MethodsA retrospective analysis was performed on clinical data of 151 newly-diagnosed patients with epidermal growth factor receptor （EGFR）-positive advanced NSCLC in Renmin Hospital of Wuhan University from March 2018 to May 2022. The patients were divided into osimertinib group （n=53） and icotinib group （n=98） according to treatment method. The objective response rate （ORR），disease control rate （DCR），progression-free survival （PFS） and overall survival （OS） were compared between the two groups. The factors influencing prognosis were analyzed by using Cox regression models. Subgroup analysis was performed according to metastatic site and EGFR mutation type.ResultsORR was 56.6% （30/53） and 59.2% （58/98） for patients in the osimertinib group and icotinib group，respectively，with no statistically significant difference （χ2=0.09，P=0.759）. DCR was 83.0% （44/53） and 91.8% （90/98） for patients in the osimertinib group and icotinib group，respectively，with no statistically significant difference （χ2=2.68，P=0.102）. The median PFS was 11.7 months and 11.8 months for patients in the osimertinib group and icotinib group，respectively，with no statistically significant difference （χ2=0.06，P=0.802）. The median OS was not reached for patients in both the osimertinib group and icotinib group，with no statistically significant difference （χ2<0.01，P=0.969）. The results of multivariate analysis showed that adrenal metastases （HR=1.89，95%CI： 1.04-3.41，P=0.036） was an independent prognostic factor for PFS. Gender （HR=2.22，95%CI： 1.08-4.58，P=0.031） and adrenal metastases （HR=4.87，95%CI： 1.76-13.46，P=0.002） were independent prognostic factors for OS. The results of the subgroup analysis showed that in patients with pleural metastases （median PFS： 11.7 monthsvs.9.3 months，median OS： not reachedvs.not reached），adrenal metastases （median PFS： 8.7 monthsvs.5.6 months，median OS： 20.0 monthsvs.15.3 months），19DEL mutations （median PFS： 14.5 monthsvs.13.3 months，median OS： not reachedvs. 40.7 months），the osimertinib group tended to have better survival outcomes. Conversely，in patients with contralateral lung metastases （median PFS： 8.3 monthsvs.11.2 months，median OS： not reachedvs.40.7 months），bone metastases （median PFS： 11.7 monthsvs.11.8 months，median OS： not reachedvs.34.5 months），liver metastases （median PFS： 8.7 monthsvs.9.1 months，median OS： not reachedvs.23.8 months），brain metastases （median PFS： 11.7 monthsvs.15.3 months，median OS： 22.4 monthsvs.35.3 months） and 21L858R mutations （median PFS： 9.5 monthsvs.10.0 months，median OS： 22.4 monthsvs.not reached），the icotinib group tended to have better survival outcomes，but with no statistically significant differences （allP>0.05）.ConclusionBoth osimertinib and icotinib have good therapeutic efficacy in patients with EGFR-positive advanced NSCLC，thus can be used as first-line treatment options. Table and Figures|Reference|Related Articles|Metrics|Comments（0）

Select

Role of tertiary lymphoid structures in tumor immune microenvironment regulation and anti-tumor therapy Cao Mengqing, Xu Zhiyong, Shi Yuting, Wang Kai Journal of International Oncology 2023, 50 (3): 169-173. DOI:10.3760/cma.j.cn371439-20221121-00033 Abstract（ 260） HTML（ 6） PDF（pc）（738KB）（ 137） Knowledge map Save Tertiary lymphoid structures （TLSs） is important channel for tumor immune cell infiltration. The existence of tumor TLSs is not only related to the prognosis of patients， but also to the efficacy of a variety of anti-tumor therapies. To explore the function and immunomodulatory mechanism of TLSs and its potential value as a tumor prognostic biomarker in comprehensive anti-tumor therapy will provide new ideas for follow-up research. Reference|Related Articles|Metrics|Comments（0）

Select

Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer Zhou Ting, Xu Shaohua, Mei Lin Journal of International Oncology 2023, 50 (3): 144-149. DOI:10.3760/cma.j.cn371439-20230116-00029 Abstract（ 345） HTML（ 25） PDF（pc）（861KB）（ 136） Knowledge map Save ObjectiveTo investigate the efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer.MethodsSeventy-six patients with advanced breast cancer who were diagnosed in the Cancer Center of the People's Liberation Army Navy Anqing Hospital from August 2019 to May 2021 were selected. According to different treatment schemes， the patients were divided into the control group （using single drug capecitabine） and the test group （using bevacizumab combined with capecitabine）， with 38 cases in each group. After 4 cycles of treatment， the clinical efficacy， progression-free survival （PFS）， overall survival （OS） and adverse reactions were compared between the two groups， and the levels of vascular endothelial growth factor （VEGF）-121， VEGF-145， VEGF-165 and quality of life before and after treatment were compared.ResultsThe objective remission rate of the test group [57.89% （22/38）] was higher than that of the control group [42.11% （16/38）]， but there was no statistically significant difference （χ2=1.89，P=0.169）； The disease control rate of the test group [81.58% （31/38）] was better than that of the control group [55.26% （21/38）]， there was a statistically significant difference （χ2=6.09，P=0.014）. The median PFS of patients in the test group （6.3 months） was longer than that in the control group （4.2 months）， there was a statistically significant difference （χ2=0.48，P=0.003）； The median OS of patients in the test group （14.8 months） was not significantly different from that in the control group （13.2 months） （χ2=0.15，P=0.704）. After treatment， the expression level of serum VEGF-121 [（201.25±18.37） ng/Lvs.（276.83±20.26） ng/L]， VEGF-145 [（102.24±12.16） ng/Lvs.（170.39±15.28） ng/L]， VEGF-165 [（135.08±14.32） ng/Lvs.（210.53±16.09） ng/L] in the test group was lower than that in the control group， there were statistically significant differences （t=17.03，P<0.001；t=21.51，P<0.001；t=21.59，P<0.001）. After treatment， patients in the test group were assessed according to 36-item Short-Form （SF-36） physiological function [（80.18±13.96） scorevs.（71.72±16.12） score]， physiological function [（67.19±30.62） scorevs.（53.12±9.86） score]， physical pain [（70.01±17.97） scorevs.（61.06±17.57） score]， overall health [（68.67±18.92） scorevs.（57.96±20.97） score]， vitality [（78.39±19.37） scorevs.（68.26±18.52） score]， social function [（82.24±19.73） scorevs.（70.92±20.31） score]， the scores of emotional function [（73.81±28.86） scorevs.（60.23±29.19） score] and mental health [（76.19±12.82） scorevs.（70.31±12.54） score] were higher than those of the control group， there were statistically significant differences （t=2.45，P=0.017；t=2.03，P=0.046；t=2.19，P=0.031；t=2.34，P=0.022；t=2.33，P=0.023；t=2.46，P=0.016；t=2.04，P=0.045；t=2.02，P=0.047）. The incidence of adverse reactions in the test group [18.42% （7/38）] was lower than that in the control group [76.32% （29/38）]， there was a statistically significant difference （χ2=25.54，P<0.001）.ConclusionThe combination of bevacizumab and capecitabine chemotherapy has a higher clinical effect on advanced breast cancer， which can significantly reduce the level of VEGF in patients， improve the quality of life of patients， with mild adverse reactions and high safety. Table and Figures|Reference|Related Articles|Metrics|Comments（0）

Select

Analyzing and monitoring real-world clinical safety of ensartinib for the treatment of patients with ALK-positive non-small cell lung cancer Yuan Xiaobin, Wang Yang, Yang Min, Wu Pengxiang, Shen Zhilin, Ma Yongbin, Ding Lieming Journal of International Oncology 2023, 50 (3): 150-156. DOI:10.3760/cma.j.cn371439-20221230-00030 Abstract（ 221） HTML（ 12） PDF（pc）（763KB）（ 135） Knowledge map Save ObjectiveTo evaluate the safety of ensartinib in the treatment of anaplastic lymphoma kinase （ALK）-positive non-small cell lung cancer （NSCLC） in the real-world clinical setting.MethodsClinical data of 2 221 patients with ALK-positive locally advanced or metastatic NSCLC who received ensartinib treatment （225 mg/d） from December 16， 2020 to December 16， 2021 were collected and analyzed to assess drug adverse reactions in all population including elderly patients （≥ 65 years old）.ResultsAmong the total 2 221 patients， 511 patients （23.01%） experienced adverse events， including 8 patients （0.36%） who experienced serious adverse events. Adverse events led to dose modification in 67 patients （3.02%） and discontinuation in 18 patients （0.81%）. The common adverse events were rash （407/2 221， 18.33%）， pruritus （41/2 221， 1.85%）， constipation （41/2 221， 1.85%）， and facial edema （31/2 221，1.40%）. Thirty-six patients （1.62%） experienced ≥grade 3 adverse events. After symptomatic treatment of 511 patients with adverse reactions， 50 patients （9.78%） were healed， 271 patients （53.03%） were improved， 120 patients （23.48%） were persisted， and 70 patients （13.71%） were unknown due to loss of follow-up or other reasons. Forty-three patients （1.94%） reported 57 unintended adverse reactions. Among the 599 elderly patients， 116 patients （19.37%） experienced adverse events， including 1 patient （0.17%） who experienced serious adverse events. Adverse events led to dose modification in 25 patients （4.17%） and discontinuation in 5 patients （0.83%）. The common adverse events of elderly patients were rash （88/599， 14.69%）， constipation （14/599， 2.34%）， facial edema （12/599， 2.00%）， and pruritus （10/599， 1.67%）. Twelve patients （2.00%） experienced ≥grade 3 adverse events. Among the 116 elderly patients with adverse reactions following the symptomatic treatment， 11 patients （9.48%） were healed， 58 patients （50.00%） were improved， 28 patients （24.13%） were persisted， and 19 patients （16.39%） were unknown due to loss of follow-up or other reasons. During the treatment， 1 patient （0.05%） experienced grade 2 interstitial lung disease， and no patient died due to adverse events.ConclusionEnsartinib has a favorable safety profile in the real-world populations， with the most frequent adverse events being rash， mostly mild， and low incidence of ≥grade 3 adverse events. Overall， adverse reactions were tolerable and manageable. Table and Figures|Reference|Related Articles|Metrics|Comments（0）

Select

Research progress of primary pulmonary lymphoepithelioma-like carcinoma Ma Pengcheng, Chen Yu Journal of International Oncology 2023, 50 (3): 174-178. DOI:10.3760/cma.j.cn371439-20221121-00034 Abstract（ 246） HTML（ 10） PDF（pc）（741KB）（ 131） Knowledge map Save Primary pulmonary lymphoepithelioma-like carcinoma （PPLELC） is a distinct type of lung cancer with histological profiles similar to nasopharyngeal carcinoma. The development is associated with EBV and plasma EBV DNA has predictive value in the progression and prognosis of PPLELC. PPLELC is different from some other types of lung cancer in that it has a low mutation rate of the classical lung cancer driver genes and targeted therapy is ineffective for it. Chemotherapy combined with immunotherapy may be the best first-line treatment option for patients with advanced PPLELC. Reference|Related Articles|Metrics|Comments（0）

Select

Journal of International Oncology 2024, 51 (1): 1-20. DOI:10.3760/cma.j.cn371439-20231221-00001 Abstract（ 174） HTML（ 60） PDF（pc）（2788KB）（ 131） Knowledge map Save Table and Figures|Reference|Related Articles|Metrics|Comments（0）

Select

Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer Xu Liangfu, Li Yuanfei Journal of International Oncology 2023, 50 (3): 186-190. DOI:10.3760/cma.j.cn371439-20221213-00037 Abstract（ 211） HTML（ 5） PDF（pc）（716KB）（ 127） Knowledge map Save In recent years， immunotherapy， especially immune checkpoint inhibitors， has shown obvious advantages in prolonging the survival of patients with advanced tumors， and the tumor microenvironment is one of the important factors affecting the efficacy of immunity. Patients with microsatellite-stable colorectal cancer exhibit immune responses in combination with immune checkpoint inhibitor therapy. In-depth exploration of the tumor microenvironment characteristics of microsatellite-stable colorectal cancer and the application of combined immune checkpoint inhibitor therapy can provide new ideas and directions for colorectal cancer immunotherapy. Reference|Related Articles|Metrics|Comments（0）

Select

Journal of International Oncology 2022, 49 (12): 766-768. DOI:10.3760/cma.j.cn371439-20220816-00151 Abstract（ 120） HTML（ 9） PDF（pc）（979KB）（ 123） Knowledge map Save Table and Figures|Reference|Related Articles|Metrics|Comments（0）

Select

Level and diagnostic value of serum insulin-like growth factor binding protein 7 in patients with gastric cancer Liu Cantong, Huang Xinyi, Chen Liuyi, Chen Hao, Peng Yuhui, Huang Xuchun Journal of International Oncology 2022, 49 (12): 724-728. DOI:10.3760/cma.j.cn371439-20220609-00142 Abstract（ 194） HTML（ 11） PDF（pc）（1091KB）（ 119） Knowledge map Save ObjectiveTo investigate the serum level of insulin-like growth factor binding protein 7 （IGFBP7） in patients with gastric cancer and its diagnostic significance.MethodsA total of 100 gastric cancer patients （gastric cancer group） including 49 patients with early gastric cancer （early gastric cancer group）, who were hospitalized in Sun Yat-sen University Cancer Center from May to December 2019 were selected as the research subjects, and 94 physical examination subjects during the same period were selected as the normal control group. The levels of serum IGFBP7 were detected by enzyme-linked immunosorbent assay. At the same time, the laboratory carcinoembryonic antigen （CEA） test results were collected. The relationships between the level of serum IGFBP7 and the clinicopathological features of gastric cancer patients were analyzed. The diagnostic value was evaluated by receiver operating characteristic （ROC） curve.ResultsThe level of serum IGFBP7 in the gastric cancer group was （1.595±0.159） ng/ml, and that in the normal control group was （1.850±0.328） ng/ml, with a statistically significant difference （t=-0.26,P<0.001）, and among them, the level of serum IGFBP7 in the early gastric cancer group was （1.601±0.153） ng/ml, and there was a statistically significant difference compared with the normal control group （t=-0.26,P<0.001）. The level of serum CEA in the gastric cancer group was 2.230 （2.043） ng/ml, and that in the normal control group was 1.805 （1.020） ng/ml, with a statistically significant difference （U=0.45,P=0.004）, and among them, the level of serum CEA in the early gastric cancer group was 2.220 （1.780） ng/ml, and there was a statistically significant difference compared with the normal control group （U=0.53,P=0.002）. There were no significant correlations between IGFBP7 and CEA level （χ2=0.36,P=0.547）, age （χ2=0.16,P=0.688）, gender （χ2=0.97,P=0.326）, depth of invasion （χ2=0.30,P=0.585）, lymph node metastasis （χ2=0.17,P=0.684）, distant metastasis （χ2=0.09,P=0.767） and TNM stage （χ2=0.38,P=0.537）. ROC curve analysis showed that the area under the curve （AUC） of IGFBP7 for gastric cancer diagnosis was 0.84 （95%CI: 0.78-0.89）, the AUC of CEA for gastric cancer diagnosis was 0.62 （95%CI: 0.54-0.70）, and there was a statistically significant difference （Z=4.33,P<0.001）. The AUC of IGFBP7 combined with CEA for gastric cancer diagnosis was 0.85 （95%CI: 0.79-0.90）. Compared with CEA alone, there was a statistically significant difference （Z=4.97,P<0.001）. Compared with IGFBP7 alone, there was no statistically significant difference （Z=1.41,P=0.159）. The AUC of IGFBP7 in the diagnosis of early gastric cancer was 0.84 （95%CI: 0.78-0.91）, the AUC of CEA in the diagnosis of early gastric cancer was 0.66 （95%CI: 0.56-0.75）, and there was a statistically significant difference （Z=3.11,P=0.002）. The AUC of IGFBP7 combined with CEA in the diagnosis of early gastric cancer was 0.85 （95%CI: 0.78-0.91）. Compared with CEA alone, there was a statistically significant difference （Z=3.54,P<0.001）. Compared with IGFBP7 alone, there was no statistically significant difference （Z=1.19,P=0.232）.ConclusionThe serum IGFBP7 level of gastric cancer patients is lower than that of normal controls. Compared with CEA, serum IGFBP7 has better diagnostic value for gastric cancer. Table and Figures|Reference|Related Articles|Metrics|Comments（0）

Select

Clinical research progress of immunotherapy for nasopharyngeal carcinoma Gu Anqin, Long Jinhua, Jin Feng Journal of International Oncology 2023, 50 (5): 299-303. DOI:10.3760/cma.j.cn371439-20230120-00060 Abstract（ 176） HTML（ 5） PDF（pc）（730KB）（ 119） Knowledge map Save Immunotherapy mainly uses the effector units of the body's immune system to overcome the immune escape or adaptive immune resistance of tumors， accurately identify and remove tumor cells， and normalize or enhance the function of the immune system， which mainly includes cytokine therapy， immune checkpoint inhibition therapy， adoptive cell immunotherapy， tumor vaccine and antibody targeted therapy. The immune characteristics of nasopharyngeal carcinoma make the patients potentially suitable for immunotherapy or combined therapy with radiotherapy and chemotherapy. In recent years， PD-1 inhibitors alone and in combination with chemotherapy have shown good anti-tumor activity and safety in the treatment of recurrent/metastatic nasopharyngeal carcinoma. The incorporation of immune checkpoint inhibitors into the treatment paradigms of nasopharyngeal carcinoma has become a clinical research hot spot. Reference|Related Articles|Metrics|Comments（0）

Select

Effects of GCSH gene on proliferation and apoptosis of gastric cancer SNU-1 cells Yang Ya, Wang Huili, Liu Yan, Guo Jinfeng, Wang Chunxia, Lyu Min, Shan Changping Journal of International Oncology 2023, 50 (5): 257-262. DOI:10.3760/cma.j.cn371439-20230302-00052 Abstract（ 162） HTML（ 24） PDF（pc）（1829KB）（ 118） Knowledge map Save ObjectiveTo explore the effects of knocking down glycine cleavage system H protein（GCSH） on proliferation， apoptosis， oxidative stress and migration of gastric cancer SNU-1 cellsin vitro.MethodsSNU-1 cells were culturedin vitroand divided into control group （no transfection）， negative control group （transfection of negative control siRNA） and GCSH knockdown group （transfection of GCSH siRNA）. Quantitative PCR was used to detect the knockdown effect. Immunofluorescence was used to observe the morphology of cells in each group. CCK-8 was used to test the proliferation of SNU-1 cells. Flow cytometry was used to detect the apoptosis and oxidative stress level， and scratch test was used to detect the cell migration.ResultsQuantitative PCR experiment showed that the relative expression levels of GCSH in the control group， negative control group and GCSH knockdown group were 1.29±0.16， 1.36±0.17 and 0.32±0.04， respectively （F=90.32，P<0.001）. There was no significant difference between the control group and negative control group （P=0.497）. Compared to the negative control group， the GCSH knockdown group was significantly decreased （P<0.001）. Immunofluorescence experiment showed no significant difference in the morphology of cells among the groups. The CCK-8 experiment results showed that the cell proliferation activities of the control group， negative control group and GCSH knockdown group were 2.63±0.12， 2.61±0.14， 2.45±0.14， respectively （F=6.35，P=0.005）. There was no significant difference between the control group and negative control group （P=0.751）， and the GCSH knockdown group significantly decreased compared to the negative control group （P=0.011）. The results of flow cytometry showed that the early stage apoptosis rates of SNU-1 cells in the control group， negative control group and GCSH knockdown group were （13.38±0.45）%， （12.86±0.65）%， （20.04±3.61）%， respectively （F=15.37，P<0.001）. There was no significant difference between the control group and negative control group （P=0.559）. Compared to the negative control group， the GCSH knockdown group significantly increased （P=0.002）. The late stage apoptosis rates of the three groups were （2.21±0.25）%， （2.68±0.45）%， （5.67±1.67）%， respectively （F=18.24，P<0.001）. There was no significant difference between the control group and negative control group （P=0.356）. Compared to the negative control group， the GCSH knockdown group showed a significant increase （P=0.024）. The reactive oxygen species positive rates in the control group， negative control group and GCSH knockdown group were （26.98±8.79）%， （28.27±5.63）%， （48.41±0.94）%， respectively （F=22.56，P<0.001）. There was no significant difference between the control group and negative control group （P=0.950）. Compared to the negative control group， the GCSH knockdown group significantly increased （P<0.001）. The cell migration rates of the control group， negative control group and GCSH knockdown group were （48.29±5.79）%， （51.66±2.29）%， （14.01±1.56）%， respectively （F=148.80，P<0.001）. There was no significant difference between the control group and negative control group （P=0.328）. Compared with the negative control group， the GCSH knockdown group significantly decreased （P<0.001）.ConclusionKnock down of GCSH gene can inhibit the proliferation and migration， increase cell apoptosis rate and oxidative stress of SNU-1 cellsin vitro. GCSH gene may be a potential target for the treatment of gastric cancer. Table and Figures|Reference|Related Articles|Metrics|Comments（0）